July 25, 2017 07:50 AM EDT
R&D
Pharma

Bio­gen lays out a plan to “stream­line” ops, add $400M to fund neu­ro­sciences R&D, new deals

John Carroll

Editor & Founder

Bio­gen saw its share price $BI­IB pop up more than 5% Tues­day morn­ing as the com­pa­ny re­port­ed sharply high­er rev­enue for Spin­raza, in­di­cat­ing that they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times